Sandu Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for Friday, September 11, 2026. The meeting will be conducted via Video Conference or Other Audio-Visual Means in compliance with SEBI regulations and the Companies Act, 2013.

Meeting Details

The AGM is set to begin at 4:30 pm IST. Shareholders can access the Notice of AGM, explanatory statements, and the Annual Report for FY26 from the company’s website and the BSE Limited portal. The notice was published in Navhind Times and Navprabha on August 20, 2026.

E-Voting Process

Members holding shares as of the cut-off date of Friday, September 4, 2026, are eligible to vote. The company has enabled remote e-voting through National Securities Depository Limited (NSDL).

• Remote E-Voting Window: Commences at 10:00 am IST on Tuesday, September 8, 2026, and ends at 5:00 pm IST on Thursday, September 10, 2026.
• Voting During AGM: Members present via VC/OAVM who have not voted remotely may cast their votes during the meeting.
• Scrutinizer: Swapnil Dixit, ACS, of M/s. Swapnil J Dixit & Associates, has been appointed to scrutinize the voting process.

Record Date and Dividend

The Register of Members and Share Transfer Books will remain closed from September 4, 2026, to September 11, 2026, inclusive. Any dividend declared for FY26 will be paid to members recorded on the register as of the cut-off date.

Sandu Pharmaceuticals reported a net profit of ₹22.82 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a 2.2% year-on-year increase from ₹22.33 lakh in Q1FY26. Revenue from operations declined 1.9% to ₹1,638.88 lakh, while total expenses were contained at ₹1,604.57 lakh. Earnings per share (basic) increased to ₹0.37 from ₹0.23.

For the full financial year ended March 31, 2026 (FY26), the company recorded a 23.2% increase in net profit to ₹176.62 lakh compared to ₹154.89 lakh in FY25. Revenue from operations rose 4.1% to ₹6,993.45 lakh from ₹6,719.24 lakh in the previous year. Total income stood at ₹7,037.89 lakh, while total expenses were ₹6,772.34 lakh. Profit before tax grew 23.2% to ₹265.56 lakh. Earnings per share (basic) improved to ₹1.83 from ₹1.60 in the prior year.

Financial Performance Highlights

The Board of Directors approved the unaudited standalone financial results on August 11, 2026. The company also announced that its 41st Annual General Meeting (AGM) will be held on September 11, 2026, via Video Conferencing. The Register of Members will remain closed from September 4, 2026, to September 11, 2026.

Auditor Appointment and Related Party Transactions

The Board recommended the appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a first term of five consecutive years, commencing from the conclusion of the ensuing AGM until the AGM in 2031. This appointment is subject to shareholder approval. Additionally, the Board sought member approval for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.

What the Numbers Show

Despite a marginal decline in top-line revenue in Q1FY27, Sandu Pharmaceuticals improved its bottom line through efficient cost control. For FY26, the company achieved a healthy expansion in both revenue and profitability, with net profit growth outpacing revenue growth. The significant improvement in earnings per share underscores the impact of consistent profitability on shareholder value.